HURA FY2025 EPS Lifted by Brookline Capital Management

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Analysts at Brookline Capital Management raised their FY2025 earnings per share (EPS) estimates for shares of TuHURA Biosciences in a report released on Tuesday, November 18th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings per share of ($0.63) for the year, up from their previous forecast of ($0.65). Brookline Capital Management also issued estimates for TuHURA Biosciences’ Q4 2025 earnings at ($0.13) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at ($0.44) EPS.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01.

Several other analysts have also recently weighed in on the stock. Maxim Group lowered their price objective on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, TuHURA Biosciences currently has an average rating of “Buy” and an average price target of $10.33.

TuHURA Biosciences Price Performance

Shares of TuHURA Biosciences stock opened at $1.74 on Friday. TuHURA Biosciences has a 1 year low of $1.56 and a 1 year high of $7.20. The firm has a market cap of $89.19 million and a PE ratio of -3.48. The company has a 50 day simple moving average of $2.38 and a two-hundred day simple moving average of $2.67.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Suncoast Equity Management boosted its holdings in TuHURA Biosciences by 4.4% during the 2nd quarter. Suncoast Equity Management now owns 104,409 shares of the company’s stock valued at $233,000 after acquiring an additional 4,412 shares during the period. Virtu Financial LLC purchased a new position in TuHURA Biosciences in the 3rd quarter worth approximately $26,000. JPMorgan Chase & Co. bought a new stake in TuHURA Biosciences in the second quarter valued at approximately $27,000. Intech Investment Management LLC purchased a new stake in shares of TuHURA Biosciences during the second quarter valued at approximately $29,000. Finally, Invesco Ltd. purchased a new stake in shares of TuHURA Biosciences during the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.